Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-95
SponsorEmory University
About this trial
This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.
Eligibility criteria
Qualifiers
Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee.
Patients between the ages of 18 and 95 years.
Disqualifiers
Patients with concurrent and significant injuries to other bones or organs.
Patients with local infections.
Minors unable to provide informed consent for participation in the study.
Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.
Trial design
Treatments tested in this trial
- Suzetrigine
Treatment groups
75 Participants
are divided into 1 treatment groupSponsors and collaborators
Emory University
Lead sponsor
Vertex Pharmaceuticals Incorporated
Collaborator
Source ClinicalTrials.gov